Polypeptide with triple helix structure, recombinant XII type humanized collagen and application of recombinant XII type humanized collagen
The recombinant type XII humanized collagen developed through synthetic biology technology forms a triple helix structure, which solves the problems of low biological activity and poor stability in existing technologies, and achieves efficient expression and wide application in the fields of cell adhesion, proliferation and skin tightening and anti-wrinkle.
Patent Information
- Application Number
- CN202511604749.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-05-30
- Filing Date
- 2025-11-04
- Publication Date
- 2026-02-24
AI Technical Summary
Existing recombinant type XII collagen has problems such as unmodified post-translation, failure to form a higher triple helix conformation, low biological activity, and poor stability, which limit its application in cell adhesion and proliferation.
Using synthetic biology and structural biology techniques, a recombinant type XII humanized collagen protein capable of forming a triple helix structure was developed. By designing peptide amino acid sequences and constructing them through genetic engineering, a recombinant type XII humanized collagen protein with cell adhesion and cell proliferation promotion activities was formed.
It has achieved efficient expression and large-scale production of recombinant type XII humanized collagen, which has good biological activity and is suitable for a variety of medical and non-medical applications, including promoting cell proliferation and cell adhesion, improving the extracellular matrix, inhibiting MMP-1, reducing collagen degradation, and having skin firming and anti-wrinkle effects.